Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEROICC: Hypofractionated Radiotherapy for Cervical Cancer
NCT04583254Phase 2Recruiting
- Start
- Feb 2021
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms). Primary endpoint: Feasibility of patient accrual at 3 years. Started Feb 2021; status: recruiting.
Beyond the preview
Go deeper on NCT04583254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04583254.